Table 3

Summary of complications, number of patients, probabilities, QALY values and total costs (in £ per patient) associated with outcomes for PAE and TURP 12 months post intervention

OutcomeComplicationsTotal cost (£ per patient)*Number of patientsProbabilityAverage QALY±SDAssigned QALY for sensitivity analysis 1Assigned QALY for sensitivity analyses 2 and 3
PAE
1HU, HS, UI2010.0410.0081.00±0.000.930.89
2HU, HS, RE2000.0040.0300.97±0.020.960.89
3HU, HS2000.0060.0450.95±0.030.960.89
4HU, RE2000.0030.0230.97±0.030.960.89
5HU2000.00160.1200.97±0.030.960.89
6HS, RE2000.000.0080.97±0.000.960.89
7HS2000.0050.0380.97±0.030.960.89
8I3203.330.0080.97±0.000.890.89
9UI2010.0450.0380.93±0.050.930.89
10RE2000.0060.0450.97±0.050.960.89
11Nil2000.00850.6390.96±0.030.960.96
Total1331.0000.96±0.03
TURP
1HU, HS3028.0010.0321.00±0.000.990.89
2HU, I, RE4231.3310.0320.94±0.000.890.89
3HU, UI, RE3038.0410.0321.00±0.000.930.89
4HU, RE3028.00110.3550.98±0.030.990.89
5HU3028.0070.2260.97±0.040.990.89
6RE3028.0050.1610.98±0.020.990.89
7Nil3028.0050.1610.99±0.020.990.99
Total311.0000.98±0.03
  • *Total cost (in £ per patient) for each outcome was derived by adding the intervention cost (see table 1) to the cost of managing the observed complications (see online supplemental table S3).

  • HS, hematospermia; HU, hematuria; I, incontinence; PAE, prostate artery embolization; QALY, quality-adjusted life year; RE, retrograde ejaculation; TURP, transurethral resection of the prostate; UI, urinary infection.